The Association Between the Peroxisome Proliferator-Activated Receptor-γ2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes Mellitus: A HuGE Review and Meta-Analysis by Gouda, HN et al.
American Journal of Epidemiology
ª The Author 2010. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Vol. 171, No. 6
DOI: 10.1093/aje/kwp450
Advance Access publication:
February 23, 2010
Human Genome Epidemiology (HuGE) Review
The Association Between the Peroxisome Proliferator-Activated Receptor-g2
(PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes Mellitus: A HuGE Review
and Meta-Analysis
Hebe N. Gouda*, Gurdeep S. Sagoo, Anne-Helen Harding, Jan Yates, Manjinder S. Sandhu, and
Julian P. T. Higgins
* Correspondence to Hebe N. Gouda, Department of Public Health and Primary Care, Institute of Public Health, University of
Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0SR, United Kingdom (e-mail: hng20@medschl.cam.ac.uk).
Initially submitted June 15, 2009; accepted for publication December 15, 2009.
The peroxisome proliferator-activated receptor-c gene (PPARG) has been implicated in the etiology of type
2 diabetes mellitus and has been investigated in numerous epidemiologic studies. In this Human Genome Epi-
demiology review, the authors assessed this relation in an updated meta-analysis of 60 association studies.
Electronic literature searches were conducted on September 14, 2009. Population-based cohort, case-control,
cross-sectional, or genome-wide association studies reporting associations between the PPARG Pro12Ala gene
variant (rs1801282) and type 2 diabetes were included. An updated literature-based meta-analysis involving
32,849 type 2 diabetes cases and 47,456 controls in relation to the PPARG Pro12Ala variant was conducted.
The combined overall odds ratio, calculated by per-allele genetic model random-effects meta-analysis for type 2
diabetes and the Pro12Ala polymorphism, was 0.86 (95% conﬁdence interval: 0.81, 0.90). The analysis indicated
a moderate level of heterogeneity attributable to genuine variation in gene effect size (I2 ¼ 37%). This may reﬂect
the variation observed between ethnic populations and/or differences in body mass index. Work on PPARG
Pro12Ala should now focus on the observed heterogeneity in the magnitude of the association between popula-
tions. Further investigations into gene-gene and gene-environment interactions may prove enlightening.
diabetes mellitus, type 2; epidemiology; genetics; genome, human; meta-analysis; PPAR gamma; review
Abbreviations: BMI, body mass index; CI, conﬁdence interval; EPIC, European Prospective Investigation Into Cancer and
Nutrition; HuGE, Human Genome Epidemiology; PPARG, peroxisome proliferator-activated receptor-c; SNP, single nucleotide
polymorphism.
Editor’s note: This article also appears on the Web site of
the Human Genome Epidemiology Network (http://www.
hugenet.org.uk/index.html).
BACKGROUND
Gene/gene variants
The peroxisome proliferator-activated receptors (PPAR-
a, PPAR-d, and PPAR-c) are transcription factors belonging
to the nuclear hormone receptor superfamily (1). These re-
ceptors combine with the retinoid X receptors to form het-
erodimers that regulate various genes involved in lipid and
glucose metabolism, fatty acid transport, adipocyte differ-
entiation, carcinogenesis, and inflammation (2–4). Here we
consider the relation between the peroxisome proliferator-
activated receptor-c2 (PPARG2) gene and type 2 diabetes.
The PPARG gene is located on chromosome 3p25
(OMIM number 601487) and encodes a nuclear transcrip-
tion factor involved in the expression of hundreds of genes.
The PPARG gene contains 9 exons, spans more than 100
kilobases, and, because of alternative mRNA splicing,
results in the production of 2 protein isoforms, PPARG1
and PPARG2 (5). PPARG1 is encoded by 8 exons, using
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exons 1–6, A1, and A2, with PPARG2 being encoded using
exons 1–6 and B. While PPARG1 is found ubiquitously in
the body, PPARG2 is largely found in adipose tissue and
the large intestine (5). Several variants in the PPARG gene
have been identified, with the Pro12Ala variant having been
the most extensively examined in epidemiologic studies.
The PPARG gene locus and gene variants have previously
been addressed in a Human Genome Epidemiology (HuGE)
review on the genetics of leptin and obesity (6). The as-
sociation between the Pro12Ala variant (rs1801282) and
type 2 diabetes has been the focus of several meta-analyses
(Table 1).
Gene variant frequency
Yen et al. (7) first identified a missense mutation resulting
in the alanine substitution for proline at codon 12 of the
PPARG gene. The frequency of the 12Ala allele has been
found to range from 2% to 18% in healthy people (6). We
estimated Pro12Ala allele frequencies from the control
groups of all studies identified for inclusion in the present
review (see Web Table 1, which is posted on the Journal’s
Web site (http://aje.oxfordjournals.org/)). Across all studies,
the frequency of the 12Ala allele in control groups ranged
from 1.7% to 21.6% (median, 9.5%). In the studies reporting
controls as ethnically Caucasian, the 12Ala allele frequency
ranged from 5.9% to 21.6% (median, 12.7%). In studies
reporting controls as ethnically of East Asian descent (such
as Chinese or Japanese), the 12Ala allele frequency ranged
from 1.7% to 9.3% (median, 4.5%).
Disease
By the year 2030, diabetes mellitus is expected to affect
almost 5% of the world’s population—an estimated 366
million people (8). The vast majority of these cases will
be type 2 diabetes, with current diagnoses currently ac-
counting for approximately 90%–95% of diabetes cases.
Diabetes prevalence is currently about 3% in the general
population, with increased prevalence in some ethnic
minority groups (such as South Asians, Africans, Afro-
Caribbeans, and Chinese), as well as in less affluent popu-
lations, including those that are less physically active, have
central obesity, and have a high body mass index (BMI;
weight (kg)/height (m)2). Some populations, such as Pima
Indians, Australian Aboriginal communities, and Pacific
and Indian Ocean Islanders, have a far higher prevalence,
at up to 40% (9). The presence of diabetes mellitus is as-
sociated with a range of vascular complications (such as
myocardial infarction, stroke, heart failure, renal failure,
angina, and retinopathy) leading to a reduced life expec-
tancy and a reduced quality of life (10). The large and in-
creasing burden of type 2 diabetes and the potential for
modifying risk through adequate treatments and lifestyle
alterations make the identification of methods for the early
detection of persons at greater risk an important public
health challenge.
Knowledge of genetic polymorphisms that allow accurate
quantification of type 2 diabetes risk will allow the devel-
opment of complex models with diagnostic and prognostic
potential. Several extensive reviews have summarized find-
ings on the genetic epidemiology of type 2 diabetes (11–13).
However, substantial advances have been made in the past
few years, with an increase in confirmed type 2 diabetes
susceptibility loci from 3 genes (PPARG, KCNJ11, and
TCF7L2) to almost 20 (with newly identified variants in
the following genes: ADAMTS9, CDKAL1, CDKN2A/B,
CAMK1D, FTO, HHEX/IDE, HNF1B, IGF2BP2, JAZF1,
MTNR1B, NOTCH2, SLC30A8, THADA, TSPAN8, and
WFS1) (14–17). This major step forward has been due
mainly to advances in technology, with genome-wide asso-
ciation scans now allowing unprecedented progress to be
made in the understanding of the genetic etiology of several
complex diseases, including type 2 diabetes. It is increas-
ingly evident that the genetic basis of type 2 diabetes in-
volves multiple genes that each have a modest effect size on
diabetes susceptibility and that interaction with other sus-
ceptibility loci and/or environmental factors may result in
more substantial effects.
Objectives
The association between the PPARG2 Pro12Ala gene
variant and type 2 diabetes has been investigated in numer-
ous epidemiologic studies since it was first suggested in
1998 that carriers of the 12Ala variant showed a 75% re-
duction in risk of type 2 diabetes (see Web reference 1 (W1),
which is listed in Web Appendix 1 on the Journal’s Web site
(http://aje.oxfordjournals.org/)). Here we evaluate the evi-
dence for an association between the PPARG2 Pro12Ala
(rs1801282) gene variant and type 2 diabetes using methods
developed by the Human Genome Epidemiology Network
and the Cochrane Collaboration (18–20). We report results
from an updated meta-analysis of 60 association studies,
involving a total of 32,849 type 2 diabetes cases and
47,456 controls in relation to the Pro12Ala gene variant in
the PPARG gene. The present report primarily focuses on
population association studies (including case-control, co-
hort, and genome-wide association studies but excluding
family-based studies) and contains an investigation of
potential sources of heterogeneity.
MATERIALS AND METHODS
Selection criteria and identiﬁcation of studies
Eligible for inclusion were all population-based cohort,
case-control, or cross-sectional studies reporting on associ-
ations between the PPARG2 Pro12Ala variant and type 2 di-
abetes. We performed electronic searches, not limited to the
English language, of Medline (using PubMed), EMBASE,
HuGE Navigator, Web of Science, and the Science Citation
Index using the search method described inWeb Appendix 2
(http://aje.oxfordjournals.org/). The latest searches were un-
dertaken on September 14, 2009. All relevant articles iden-
tified through the search were scanned on the basis of title,
keywords, and abstract (where available) by one of us and
were rejected in the initial screening if the article clearly did
not meet the inclusion criteria. Where a title/abstract could
not be rejected with certainty, we obtained the full text of the
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Table 1. Findings From Previously Conducted Meta-Analyses of the Peroxisome Proliferator-Activated Receptor-c2 (PPARG2) Pro12Ala Gene Variant and Type 2 Diabetes, 2000–2007
Study and
Year (Ref.)
Study Details
No. of
Studies
No. of
Cases
No. of
Controls
Main Analyses Subanalyses
OR 95% CI Subgroup OR 95% CI
Altshuler et al.,
2000 (30)
Very little detail presented. 8 NS NS 0.79 0.70, 0.89a NS
Ek et al., 2001 (31) Meta-analysis (using Mantel-
Haenszel method) of published
case-control studies.
10 3,032 3,812 0.81 0.72. 0.91 Caucasian
participants
0.85 0.76, 0.96
East Asian
participants
0.42 0.26, 0.67
Lohmueller et al.,
2003 (34)
Meta-analysis (using both ﬁxed-
effect and random-effects
methods) of published
case-control studies.
14 NS NS 1.22b 1.08, 1.37 Random effectsb 1.21 1.07, 1.37
Hara et al., 2003 (33) Meta-analysis in a Japanese
publication.
8 NS NS 0.81c 0.78, 0.93c NS
Parikh and Groop,
2004 (35)
Meta-analysis (using Mantel-Haenszel
method) of published studies.
23 NS NS 0.79 NS NS
Vardarli, 2007 (32) Abstract of meta-analysis (using
DerSimonian and Laird (24)
random-effects method) of
published studies.
33 14,771 14,513 0.86 0.75, 0.97 NS
Ludovico et al.,
2007 (29)
Meta-analysis (using random-effects
method and dominant genetic
model) of published and
unpublished studies.
43 19,250 23,660 0.81 0.75, 0.88 East Asian
participants
0.65 0.54, 0.79
North American
participants
0.82 0.67, 1.01
European
participants
0.86 0.79, 0.95
Northern
Europeans
0.74 0.66, 0.83
Central
Europeans
0.90 0.82, 1.00
Southern
Europeans
1.01 0.80, 1.28
Abbreviations: CI, conﬁdence interval; NS, not stated; OR, odds ratio.
a The 95% CI was estimated using the P value (P ¼ 0.0007) from the paper by Altshuler et al. (30).
b The risk allele was deﬁned as Pro12.
c The OR and 95% CI were estimated from Figure 9 in the paper by Hara et al. (33).
P
P
A
R
G
P
ro
1
2
A
la
G
e
n
e
V
a
ria
n
t
a
n
d
T
y
p
e
2
D
ia
b
e
te
s
6
4
7
A
m
J
E
p
id
e
m
io
l
2
0
1
0
;1
7
1
:6
4
5
–
6
5
5
article for evaluation. We also reviewed the reference lists of
retrieved articles to identify other relevant publications.
In addition, we searched specifically for genome-wide
association studies of type 2 diabetes using the catalog of
published genome-wide association studies (21). The latest
searches were undertaken on September 14, 2009. The full
text and any supplementary materials were collected for
each study identified. Data for the Pro12Ala single nucleo-
tide polymorphism (SNP) (rs1801282) were extracted from
each report, and study authors were contacted if insufficient
data were reported.
Data collection
The following data were extracted independently by at
least 2 investigators, using a piloted data extraction form
(with any discrepancies being resolved by discussion and,
when necessary, adjudicated by a third reviewer): genotype
frequencies by case/control status; mean ages of cases and
controls; proportions of males and ethnic subgroups (de-
fined as people of European continental ancestry, East Asian
ancestry, or other); genotyping methods; and blinding of
laboratory workers to participant case/control status. We
calculated allele frequencies from control groups of studies
that presented data on all 3 genotype groups, assuming
Hardy-Weinberg equilibrium where appropriate. Where
there were multiple publications from the same study group,
we extracted data from each report and selected only the
most complete and up-to-date data. When articles presented
data for different ethnic groups or different case or control
sources, results for the subgroups were considered as sepa-
rate studies. Where data could not be extracted for inclusion
in the meta-analysis, the investigators were contacted via
letter and e-mail. Selected articles also included 4 Chinese-
language publications, from which data were available from
the English-language abstract (W2–W5).
Data analysis
The primary analyses for which results are presented
were conducted using a per-allele inheritance model. This
was the model favored by an initial analysis using the
inheritance-model-free analysis of Minelli et al. (22) (data
not shown). We estimated the per-allele odds ratio using
logistic regression within each study. We used funnel plots
and associated tests to assess assumptions involved in meta-
analysis and to explore the relation between precision and
magnitude of association (23). The meta-analyses used
a standard approach, weighting by precision and incorpo-
rating random effects to allow for the variation in true as-
sociations across studies (24). We performed a cumulative
meta-analysis to demonstrate how evidence concerning the
genetic association has evolved over time.
Consistency of the gene effect sizes across studies was
assessed using a test for heterogeneity and the I2 statistic,
which describes the percentage of total variation in point
estimates attributable to genuine variation rather than sam-
pling error (25). We further explored this variation by pre-
specified subgrouping of studies according to sample size
(<100, 100–499, or 500), ethnicity (Caucasian or East
Asian), source of controls (general population or hospital),
study design (retrospective or prospective), and blinding of
genotyping to clinical outcome (yes, no, or unknown). We
used random-effects meta-regression to explore the extent to
which these subgroups could explain the between-study var-
iance. Fixed-effect meta-analyses were conducted as sensi-
tivity analyses. All ranges presented are 95% confidence
intervals unless otherwise specified.
Only summary meta-analysis results were available from
Zeggini et al. (26). Their analysis used imputed and geno-
typed data for the SYN2/PPARG region, including either the
rs17036101 SNP or the rs1801282 SNP, as these 2 SNPs
represent the same association signal. Using the rs17036101
SNP as a proxy for rs1801282, we combined a random-
effects meta-analysis result from Zeggini et al. (26) with a
random-effects meta-analysis of nonoverlapping studies
from our own searches. We first computed the summary log
odds ratio and its variance for each data source and then
computed the total sumofweights and the total sumof (weight
3 log odds ratios) across both sources, and used these to
produce an overall summary estimate and variance. This is
equivalent to a standard random-effects meta-analysis, with
the exception that an estimate of between-study variance
among Zeggini et al.’s (26) studies is used in the weights for
those studies and an estimate of between-study variance
among our studies is used in the weights for our studies.
RESULTS
Characteristics of the included studies
Our literature searches yielded 1,734 reports, from which
74 eligible studies were identified, in addition to 30 genome-
wide association studies (W1–W85) (Web Table 1 and
Tables 2 and 3). Sixty-six studies (Web Table 1) contributed
to the present review (W1–W7, W9–W14, W17, W19–
W21, W23, W25, W27–W34, W36, W37, W40–W45,
W47–W54, W56, W59, W61, W63, W65, W67, W68,
W70, W72, W74, W79, W80, W83, W85). Nine studies
from 7 papers (W35, W46, W55, W57, W77, W78, W81)
(comprising approximately 7% of eligible cases and 10% of
eligible controls) could not be included because of insuffi-
cient detail and lack of response from authors after our
attempts at correspondence (Table 2). Researchers from
the European Prospective Investigation Into Cancer and
Nutrition (EPIC) provided unpublished data. Study-level
characteristics for the EPIC study (27) and the EPIC nested
case-control data have been previously published (supple-
mentary materials of Zeggini et al. (26)); summary details
are available in Web Table 2 (http://aje.oxfordjournals.org/)
andWebAppendix 3 (http://aje.oxfordjournals.org/). We also
identified 30 genome-wide association studies of type 2
diabetes in 16 papers published since 2007 (W18, W22,
W24, W26, W58, W60, W62, W64, W66, W69, W71,
W73, W75, W76, W82, W84) (see Table 3 and Web Table
3 (http://aje.oxfordjournals.org/)). Each of these studies in-
cluded either the Pro12Ala variant (rs1801282) or a nearby
tagging SNP. Zeggini et al. (26) presented results from
a meta-analysis of 59,682 participants across several of these
genome-wide association studies (W62, W64, W73, W84).
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The identified studies were published between 1998 and
2008 and were undertaken in a wide range of geographic
settings, with 66% (21,670 of 32,849) of cases having white
European continental ancestry (Caucasian), 25% (8,187 of
32,849) being East Asian, and 9% (2,992 of 32,849) having
other ethnic origins (including African-American, Ameri-
can Indian, or not stated). Nine studies were described as
prospective in design, 3 were described as cross-sectional
studies, 8 as genome-wide association studies, and 47 as
case-control studies. Thirty-one studies involved general
population-based controls, 4 involved hospital-based con-
trols, and 1 involved health-care employees; in 13 studies,
investigators did not describe the source of their controls
(see Web Table 1). In 32 studies, authors reported using
World Health Organization criteria for diagnosis of type 2
diabetes (28). Restriction fragment length polymorphism
analysis was the most common method of genotyping used.
In 23 studies, authors did not report any information on the
BMI of the case group (see Web Table 1). In 11 studies,
investigators reported information regarding age at disease
onset. Of the 67 included studies, 60 provided data for the
per-allele genetic model in our presented analyses (W1–W4,
W6, W7, W9–W14, W17–W21, W25–W33, W36, W37,
W40–W45, W47–W50, W52–W54, W56, W59, W61,
W63–W65, W67, W71, W74, W84, W85).
Two studies were found to deviate from Hardy-Weinberg
equilibrium according to the test P value (P < 0.05) (W2,
W5). Approximately 70% of the studies had fixation coef-
ficients with absolute values larger than 0.03 (median,
0.004; range, 0.072 to 0.185), with the studies evenly
distributed around zero. Authors in 42 studies reported test-
ing for Hardy-Weinberg equilibrium and found no deviation
(see Web Table 1 and Table 2).
Associations
In a random-effects meta-analysis with a per-allele genetic
model, the combined type 2 diabetes odds ratio for the
Pro12Ala polymorphism across the 66 studies was 0.86
(95% confidence interval (CI): 0.81, 0.90) (Web Figure 1
(http://aje.oxfordjournals.org/)). The fixed-effectmeta-analysis
was 0.85 (95% CI: 0.82, 0.88). The cumulative meta-analysis
illustrates the exaggerated effect often observed in the earliest
study and reveals that the accumulated evidence hovered
around the conventional 5% significance level until 2004. In
studies published between 2004 and 2008, the overall P value
was reduced from 0.028 to 1.3 3 108.
There was evidence of a moderate degree of inconsis-
tency among these studies (I2 ¼ 37%, 95% CI: 9, 54; P ¼
0.0028), and no evidence of funnel plot asymmetry was
found either visually or using the Harbord test (23) (P ¼
0.87). Study participant ethnicity accounted for some of this
heterogeneity (14% of the between-study variance). Results
from subgroup analyses are presented in Figure 1. When we
considered only the large (>500 cases) studies, the odds
ratio was 0.84 (95% CI: 0.79, 0.90), with I2 ¼ 43% (95%
CI: 0, 66; P ¼ 0.025). When studies were subgrouped by
ethnicity, the odds ratio was nearer 1 for Caucasians (odds
ratio ¼ 0.86 (95% CI: 0.81, 0.90), I2¼ 37% (95% CI: 0, 57;
P ¼ 0.019)) than for East Asians (odds ratio ¼ 0.78 (95%Ta
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Table 3. Characteristics of the Genome-Wide Association Studies Conducted for Type 2 Diabetes, 2007–2009
Study and
Year (Ref.)
Ethnicity/
Location
Cases Controls
No. of Subjects Age at
Onset,
years (SD)
Mean Age,
years (SD)
BMIa (SD)
No. of Subjects
Mean Age,
years (SD)
BMI (SD)
Total Males Females Total Males Females
Takeuchi et al.,
2009 (W71)
Japan 1,629 928 701 NS Stage 1: 66.6 (9.8) Stage 1: 24.5 (3.6) 1,517 806 711 Stage 1: 64.7 (6.8) Stage 1: 23.3 (3.1)
Stage 2: 62.7 (11.7) Stage 2: 23.3 (3.9) Stage 2: 71.1 (9.6) Stage 2: 23.0 (3.1)
Timpson et al., 2009
(W75)—see Zeggini
et al., 2007 (W75)
United
Kingdom
Herder et al.,
2008 (W26)
Germany 433 255 178 NS 65.2 (8.3) 30.9 (5) 1,438 693 745 61.9 (10.2) 27.7 (4.3)
Unoki et al. (A),
2008 (W76)
Japan 5,149 3,112 2,037 NS 4,176 1,988 2,188
Unoki et al. (B),
2008 (W76)
Singapore 1,498 736 762 NS 63.9 (9.7) 25.3 (3.9) 1,881 828 1,053 35.4 (11.2) 22 (3.4)
Unoki et al. (C),
2008 (W76)
Denmark 4,085 2,423 1,662 NS 60 (9.8) 30.6 (5.6 5,302 2,456 2,846 46.9 (9.1) 25.6 (4)
Yasuda et al.,
2008 (W82)
Japan
Sladek et al., 2007
(W66)—initial
sample set
France 1,380 838 542 45.0 (8.4) 60.0 (10.3) 25.8 (2.8) 1,323 532 791 53.4 (5.6) 23.2 (1.8)
Sladek et al., 2007
(W66)—replication
sample set
France 2,617 1,628 989 50.4 (11.0) 62.2 (11.0) 28.9 (3.6) 2,894 1,240 1,654 56.4 (10.2) 25.3 (3.5)
Zeggini et al., 2007
(W84)—initial
sample set
United
Kingdom
1,924 1,118 806 50.3 (9.2) 58.6 (10.1) NS 2,938 1,446 1,492 NS NS
Zeggini et al., 2007
(W84)—replication
sample set
United
Kingdom
3,757 2,137 1,620 54.3 (9.4) 63.1 (9.7) NS 5,346 2,719 2,627 49.9 (16.4) NS
Steinthorsdottir
et al., 2007 (W69)
—initial sample set
Iceland 1,399 832 567 56.2 (12.3) 64.4 (12.8) 56.2 (12.3) [688]b 5,275 2,743 2,532 58.3 (17.4) 27.1 (4.9) [1,751]
Steinthorsdottir
et al., 2007 (W69)
—replication
sample set
Denmark 1,359 821 538 52.1 (10.3) [1,013] 56.8 (10.5) 29.7 (5.3) [1,343] 4,825 2,249 2,576 46.4 (8.8) 25.5 (4.1) [4,824]
Scott et al., 2007
(W64)—initial
sample set
Finland 1,161 653 508 53 63.4 29.8 1,174 574 600 64 26.8
Scott et al., 2007
(W64)—replication
sample set
Finland 1,215 724 491 56 60 30.1 1,258 768 490 59 26.4
Saxena et al., 2007
(W62)—initial
sample set
Finland 1,007 513 494 55.5 (9.7) [946] 63.4 (9.9) 28.8 (4.6) [998] 1,038 498 540 59.0 (10.2) 26.8 (3.8) [1,032]
Saxena et al., 2007
(W62)—initial
sample set
Sweden 457 228 229 59.9 (10.7) 66.0 (10.7) 28.0 (4.2) 429 209 220 58.3 (9.9) 26.4 (3.7) [420]
Saxena et al., 2007
(W62)—replication
sample set
Sweden 2,830 1,667 1,163 NS 59.0 (12.0) 29.6 (5.5) 3,550 1,340 2,210 57.0 (6.0) 25.1 (3.6)
Saxena et al., 2007
(W62)—replication
sample set
European
descent/
United States
1,226 644 582 NS 63.0 (11.0) 32.9 (6.9) 1,226 644 582 61.0 (10.0) 27.4 (5.2)
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Saxena et al., 2007
(W62)—replication
sample set
Poland 1,009 422 587 NS 62.0 (10) 29.6 (4.8) 1,009 422 587 59.0 (7.0) 26.1 (3.6)
Wellcome Trust Case-
Control Consortium,
2007 (W73)—see
Zeggini et al.,
2007 (W73)
United
Kingdom
1,924 2,938
Salonen et al., 2007
(W60)—initial
sample set
White/
European
500 228 272 NS NS NS 497 NS NS NS NS
Salonen et al., 2007
(W60)—replication
sample set
White/
European
2,573 NS NS NS NS NS 2,776 NS NS NS NS
Rampersaud et al.,
2007 (W58)—initial
sample set
Amish/
United States
124 41 83 NS 51.3 (10.5) 29.3 (5.8) 295 153 142 64.4 (12.9) 27.4 (4.7)
Rampersaud et al.,
2007 (W58)—
replication
sample set
Amish/
United States
427 200 227 51.9 (11.9) 27.7 (5.0)
Hayes et al.,
2007 (W24)
Mexican-
American
281 108 173 45.9 (10.1) 57.9 (10.7) 31.5 (6.2) 280 69 211 NS NS
Hanson et al., 2007
(W22)—initial
sample set
American Indian 300 114 186 19.2 (4.5) NS 38.9 (8.4) 334 160 174 55.5 (9.8) 35.4 (8.0)
Hanson et al., 2007
(W22)—replication
sample set
American Indian 1,207 459 748 39.7 (10.6) NS 38.3 (8.2) 1,627 748 879 27.7 (11.6) 35.6 (8.2)
Florez et al., 2007
(W18)—initial
sample set
United States 91 NS NS NS NS NS 1,087 527 560 51.5 (9.8) [1,032] 27.5 (5.2) [1,026]
Florez et al., 2007
(W18)—replication
sample set
United States 158 NS NS NS NS NS 1,465 691 774 56.1 (9.3) [1,390] 27.4 (4.8) [1,384]
Abbreviations: BMI, body mass index; NS, not stated; SD, standard deviation.
a Weight (kg)/height (m)2.
b Numbers in brackets, number of subjects.
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CI: 0.65, 0.99), I2 ¼ 45% (95% CI: 0, 69; P ¼ 0.031)),
although the difference was not statistically significant
(P ¼ 0.38). A dominant analysis of all studies composed
of Asian populations produced an odds ratio of 0.80 (95%
CI: 0.66, 0.97), with I2 ¼ 40.5% (95% CI: 0, 64).
The combined odds ratio for studies with a mean case
BMI less than 25 was 0.88 (95% CI: 0.68, 1.13), with
I2 ¼ 57% (95% CI: 0, 78; P ¼ 0.016). Studies with a mean
case BMI between 25 and 29.9 had an odds ratio of 0.84
(95% CI: 0.77, 0.91), with I2 ¼ 0% (95% CI: 0, 47; P ¼
0.45). Studies with a mean case BMI greater than or equal to
30 had an odds ratio of 0.90 (95% CI: 0.82, 0.99), with I2 ¼
46% (95% CI: 0, 68; P ¼ 0.024). A test for trend across
these 3 groups was not statistically significant (P ¼ 0.49).
No statistically significant differences were observed ac-
cording to study design. Forty case-control studies had an
odds ratio of 0.85 (95% CI: 0.79, 0.92), with I2 ¼ 44%; 9
prospective studies had an odds ratio of 0.88 (95% CI: 0.74,
1.04), with I2 ¼ 35%; and the 8 genome-wide association
studies had an odds ratio of 0.84 (95% CI: 0.79, 0.89), with
I2¼ 0%. Only 3 cross-sectional studies were available. Only
in 10 studies did authors report blinding, and among those
studies that did not report blinding status, the pooled odds
ratio was 0.86 (95% CI: 0.77, 0.97), with I2 ¼ 63.
We also investigated potential variation arising from the
use of different sources of controls. In 42 studies, investiga-
tors reported the use of a general population cohort as their
control group; the combined odds ratio was 0.86 (95% CI:
0.81, 0.91), with I2 ¼ 38%. In only 4 studies did authors
report the use of hospital-based controls; in those studies,
the odds ratio was 1.09 (95% CI: 0.86, 1.37), with I2 ¼ 0%
(P ¼ 0.06 in comparison with general population controls),
while in those studies for which authors did not state the
source of their controls (n ¼ 11), the pooled odds ratio was
0.77 (95% CI: 0.64, 0.93), with I2 ¼ 21.1% (P ¼ 0.26 in
comparison with general population controls).
We combined the random-effects meta-analysis of Zeggini
et al. (26) with our own random-effects meta-analysis of non-
overlapping published literature-based studies to produce an
overall pooled odds ratio of 0.88 (95% CI: 0.84, 0.92) involv-
ing a total of 116,040 participants (see Figure 1).
DISCUSSION
Main ﬁndings
This HuGE association review involved an updated meta-
analysis of the relation between the PPARG Pro12Ala
Subgroup No. of
Cases
Studies With >500 Cases
Caucasians
East Asians
Case BMI ≥30
Case BMI 25–29.9
Case BMI <25
Overall literature-based
Zeggini et al. (26) GWA meta-analysis (random effects)
Nonoverlapping literature-based studies (random effects)
Combined nonoverlapping and Zeggini et al. (26) (random effects)
19
34
15
16
14
9
60
23,816
21,670
8,187
10,224
5,661
7,070
32,849
27,661
37,354
5,882
14,084
8,467
5,062
47,456
No. of
Controls
0.84 (0.79, 0.90)
0.86 (0.81, 0.90)
0.78 (0.65, 0.99)
0.90 (0.82, 0.99)
0.84 (0.77, 0.91)
0.88 (0.68, 1.13)
0.86 (0.81, 0.90)
0.87 (0.83, 0.91)
0.89 (0.83, 0.95)
0.88 (0.84, 0.92)
Odds Ratio
(95%CI)
0.5 0.75 1 1.25
No. of
Studies
Odds Ratio
Figure 1. Results from random-effects meta-analyses of studies of the peroxisome proliferator-activated receptor-c2 (PPARG2) Pro12Ala gene
variant and type 2 diabetes according to various study-level characteristics. BMI, bodymass index (weight (kg)/height (m)2); CI, conﬁdence interval;
GWA, genome-wide association.
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polymorphism and type 2 diabetes among 32,849 cases and
47,456 controls in 60 studies (counting every study’s cases
and controls only once). The PPARG 12Ala polymorphism
was associated with a reduction in type 2 diabetes risk (odds
ratio ¼ 0.86, 95% CI: 0.81, 0.90), and this confirms findings
from previous meta-analyses (29–35). When only the largest
studies (>500 cases) were considered, the association re-
mained stable (odds ratio ¼ 0.84, 95% CI: 0.79, 0.90). This
work further confirms the association between the PPARG
Pro12Ala polymorphism and type 2 diabetes.
The results of the Zeggini et al. (26) meta-analysis of
genome-wide association studies were compatible with our
own literature-based meta-analysis. The Zeggini et al. anal-
ysis provided an estimate that minimized publication
bias because of the availability of genotype data from a
consortium-based approach. We pooled this estimate with
our own estimate from nonoverlapping published literature
association studies to produce an estimate for 116,040 partic-
ipants. Proposed guidelines for assessing the strength of
evidence from gene-disease association studies (36) would
designate the findings for Pro12Ala and type 2 diabetes as
‘‘strong’’ evidence (seeWebTable 4 (http://aje.oxfordjournals.
org/)).
Limitations
When interpreting these results, the potential limitations
of such a report should be considered. First, the key threat to
any literature-based review and meta-analysis is that of re-
porting bias (where only the most exciting findings are
available in the published literature). Although our own
assessments did not generally suggest the presence of ma-
terial publication bias, it is not possible to rule it out entirely
(37, 38). Given the consistency of findings between our
main analysis and our analysis of only the large (>500
cases) studies, which should have been less prone to selec-
tive reporting, we may place reasonable confidence in our
observations. Our findings were also consistent with the re-
sults from Zeggini et al.’s meta-analysis of genome-wide
association studies (26).
Consistency across studies
Overall, I2 was estimated to be 37%, with statistically
significant evidence of heterogeneity. This represents a mod-
erate level of inconsistency attributable to genuine variation
in gene effect size. It has been hypothesized in the past that
this may reflect variation between ethnic populations. We
observed a slightly higher magnitude of association in East
Asians compared with Caucasians, but the difference was
not statistically significant. Polymorphism frequencies are
known to vary by ethnicity, but the effect of this on risk
remains insufficiently studied. In the studies we identified,
the frequency of the 12Ala polymorphism in controls was
observed to be greater in Caucasian populations than in East
Asian populations.
The observed difference in the magnitude of association
between these populations may also be explained partly by
differences in BMI. In a study of French Caucasians con-
ducted by Ghoussaini et al. (W20), the presence of the Pro12
variant was observed to double the risk of type 2 diabetes in
the obese subpopulation. However, the Ala12 variant has
also been shown to be weakly associated with higher
BMI, as confirmed in a meta-analysis conducted in 2003
by Masud et al. (39).
A meta-analysis conducted by Ludovico et al. (W37)
found that the alanine polymorphism conferred significantly
greater protection against type 2 diabetes among Asians
than among Caucasians. Using 10 studies of Asian popula-
tions, their results revealed an odds ratio of 0.65 (95% CI:
0.54, 0.79). When the analysis was adjusted for BMI in the
controls, this statistical significance was lost. Furthermore,
taking into account body fat content and distribution, Radha
et al. (W57) found no protective effect of the Pro12Ala
polymorphism in South Asians.
We conducted a similar analysis of results from 20 rele-
vant studies (using a dominant model) which showed an
odds ratio of 0.80 (95% CI: 0.66, 0.97) and suggested no
difference between Asians and Caucasians (P¼ 0.59). Stud-
ies in which cases had a lower mean BMI observed a slightly
greater protective effect of the 12Ala polymorphism on
type 2 diabetes risk, but this was not statistically significant
(P ¼ 0.57; see also Figure 1).
In 2001, Luan et al. (40) hypothesized a gene-nutrient
interaction based on the ratio of polyunsaturated fats to
saturated fats which determined the association between
the Pro12Ala polymorphism and BMI. This study may con-
tribute towards an explanation of the role played by ethnic-
ity and differences in dietary habits. However, more
recently, Robitaille et al. (41) suggested an interaction in
the opposite direction, highlighting the need to carefully
assess possible interactions.
Another potential source of variation has been identified
byHegele et al. (W25) andRadha et al. (W57): These authors
noted differences in the association between Pro12Ala and
type 2 diabetes between men and women. More recently, Ali
et al. (W1),Morini et al. (42), andMattevi et al. (43) observed
a relation between the polymorphism and higher BMI inmen
which was absent in women. Since few investigators publish
their data stratified by sex, we were unable to investigate
these issues in detail. Although these investigations have
been inconsistent in the past, differences in the phenotypic
consequences of the Pro12Ala polymorphism among males
and females warrant further investigation. Further studies of
gene-gene and gene-environment interaction are necessary to
better understand these relations.
Biology
The substitution from proline to alanine at codon 12 has
been found to modulate transcriptional activity (44, 45).
This substitution is close to the NH2-terminus of the protein
in the ligand-independent activation domain, the activity of
which is potentiated through phosphorylation by insulin.
The structure and consequently the function of the protein
may be affected by this amino acid change, since alanine
favors the formation of a-helices while proline prevents it
(46). The alanine isoform leads to the less efficient stimu-
lation of PPARG target genes and predisposes people to
lower levels of adipose tissue mass accumulation, which
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in turn may improve insulin sensitivity—thus supporting
the protective effect observed for 12Ala carriers, since de-
creased insulin sensitivity plays a central role in the patho-
genesis of type 2 diabetes.
Potential public health impact and other implications of
results
There is evidence that PPARG supports the ‘‘thrifty gene
hypothesis’’ in that the wild-type genotype optimizes the
building of fat deposits as energy reserves and thus favored
human survival in times when food was either limited, spo-
radically available, or poor in quality (47–50). Because to-
day’s lifestyle is much more relaxed and sedentary and is
characterized by a diet that is rich in carbohydrates and fats
and poor in fiber, these once favorable genetic factors have
now become detrimental, leading to an increase in the risk
of developing chronic diseases such as type 2 diabetes.
PPARG is a known target for thiazolidinediones, antidia-
betic drugs which have been shown to improve insulin sen-
sitivity and to reduce plasma glucose and blood pressure in
persons with type 2 diabetes (51). Thiazolidinediones are
highly specific ligands for PPARG and lead to the activation
of the nuclear receptor on binding (52).
Since the Pro12 allele is present in at least 80% of hu-
mans, the population attributable risk of type 2 diabetes
associated with this polymorphism is as high as 25% (30).
This gene is a confirmed type 2 diabetes susceptibility locus
and is now one of almost 20 type 2 diabetes susceptibility
loci identified over the last few years. With other type 2
diabetes susceptibility loci, research on how best to use this
information in a translational context is needed. Given the
possible heterogeneity in the magnitude of the association
among populations and with environmental factors, a more
systematic assessment locus should also be used as a genetic
factor with which to investigate both gene-gene and gene-
environment interactions with type 2 diabetes.
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